Evidence of a role for RANKL in the development of myeloma bone disease

被引：20

作者：

De Leenheer, E

Mueller, GS

Vanderkerken, K

Croucher, PI

机构：

[1] Univ Sheffield, Sch Med, Bone Biol Grp, Div Clin Sci, Sheffield S10 2RX, S Yorkshire, England

[2] Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Surg, Oxford, England

[3] Free Univ Brussels, Dept Hematol & Immunol, Brussels, Belgium

来源：

CURRENT OPINION IN PHARMACOLOGY | 2004年 / 4卷 / 04期

关键词：

D O I：

10.1016/j.coph.2004.03.011

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Multiple myeloma is associated with the development of a devastating bone disease mediated by increased osteoclastic activity. The ligand for receptor activator of nuclear factor-kappaB (RANKL) plays a critical role in normal osteoclast biology and is abnormally regulated in myeloma. Targeting this system with recombinant decoy receptor, osteoprotegerin, or soluble forms of the receptor activator of nuclear factor-kappaB is able to prevent myeloma bone disease in pre-clinical models. Intriguingly, inhibiting osteoclast formation and bone resorption, and altering the bone marrow microenvironment, results in an indirect anti-myeloma effect.

引用

页码：340 / 346

页数：7

共 62 条

[11] Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma [J].

Croucher, PI ;

Shipman, CM ;

Lippitt, J ;

Perry, M ;

Asosingh, K ;

Hijzen, A ;

Brabbs, AC ;

van Beek, EJR ;

Holen, I ;

Skerry, TM ;

Dunstan, CR ;

Russell, GR ;

Van Camp, B ;

Vanderkerken, K .

BLOOD, 2001, 98 (13) :3534-3540

[12] A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype [J].

Cundy, T ;

Hegde, M ;

Naot, D ;

Chong, B ;

King, A ;

Wallace, R ;

Love, DR ;

Seidel, J ;

Fawkner, M ;

Banovic, T ;

Callon, KE ;

Grey, AB ;

Reid, IR ;

Middleton-Hardie, CA ;

Cornish, J .

HUMAN MOLECULAR GENETICS, 2002, 11 (18) :2119-2127

[13]

De Leenheer E, 2002, BLOOD, V100, p209A

[14]

Doran P, 2000, BLOOD, V96, p362A

[15]

Farrugia AN, 2003, CANCER RES, V63, P5438

[16] Apoptosis-induced by trail and TNF-α in human multiple myeloma cells is not blocked by bcl-2 [J].

Gazitt, Y ;

Shaughnessy, P ;

Montgomery, W .

CYTOKINE, 1999, 11 (12) :1010-1019

[17] Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment [J].

Giuliani, N ;

Bataille, R ;

Mancini, C ;

Lazzaretti, M ;

Barillé, S .

BLOOD, 2001, 98 (13) :3527-3533

[18] Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes:: a potential role in multiple myeloma bone disease [J].

Giuliani, N ;

Colla, S ;

Sala, R ;

Moroni, M ;

Lazzaretti, M ;

La Monica, S ;

Bonomini, S ;

Hojden, M ;

Sammarelli, G ;

Barillè, S ;

Bataille, R ;

Rizzoli, V .

BLOOD, 2002, 100 (13) :4615-4621

[19]

Heider U, 2003, CLIN CANCER RES, V9, P1436

[20] Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand [J].

Hsu, HL ;

Lacey, DL ;

Dunstan, CR ;

Solovyev, I ;

Colombero, A ;

Timms, E ;

Tan, HL ;

Elliott, G ;

Kelley, MJ ;

Sarosi, I ;

Wang, L ;

Xia, XZ ;

Elliott, R ;

Chiu, L ;

Black, T ;

Scully, S ;

Capparelli, C ;

Morony, S ;

Shimamoto, G ;

Bass, MB ;

Boyle, WJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3540-3545

← 1 2 3 4 5 6 7 →